Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.

Murmann AE, Gao QQ, Putzbach WE, Patel M, Bartom ET, Law CY, Bridgeman B, Chen S, McMahon KM, Thaxton CS, Peter ME.

EMBO Rep. 2018 Mar;19(3). pii: e45336. doi: 10.15252/embr.201745336. Epub 2018 Feb 12.

PMID:
29440125
2.

Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer.

Murmann AE, Yu J, Opal P, Peter ME.

Trends Cancer. 2018 Oct;4(10):684-700. doi: 10.1016/j.trecan.2018.08.004. Epub 2018 Sep 26. Review.

PMID:
30292352
3.

Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?

Liu W, Pfister EL, Kennington LA, Chase KO, Mueller C, DiFiglia M, Aronin N.

J Huntingtons Dis. 2016;5(1):33-8. doi: 10.3233/JHD-150183.

4.

RNA toxicity induced by expanded CAG repeats in Huntington's disease.

Martí E.

Brain Pathol. 2016 Nov;26(6):779-786. doi: 10.1111/bpa.12427. Review.

PMID:
27529325
5.

Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

Rué L, Bañez-Coronel M, Creus-Muncunill J, Giralt A, Alcalá-Vida R, Mentxaka G, Kagerbauer B, Zomeño-Abellán MT, Aranda Z, Venturi V, Pérez-Navarro E, Estivill X, Martí E.

J Clin Invest. 2016 Nov 1;126(11):4319-4330. doi: 10.1172/JCI83185. Epub 2016 Oct 10.

6.

Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.

Keeler AM, Sapp E, Chase K, Sottosanti E, Danielson E, Pfister E, Stoica L, DiFiglia M, Aronin N, Sena-Esteves M.

J Huntingtons Dis. 2016 Oct 1;5(3):239-248.

PMID:
27689620
7.

Effect of Trinucleotide Repeats in the Huntington's Gene on Intelligence.

Lee JK, Conrad A, Epping E, Mathews K, Magnotta V, Dawson JD, Nopoulos P.

EBioMedicine. 2018 May;31:47-53. doi: 10.1016/j.ebiom.2018.03.031. Epub 2018 Mar 30.

8.

Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB.

J Huntingtons Dis. 2015;4(1):17-36.

9.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

10.

A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.

Bañez-Coronel M, Porta S, Kagerbauer B, Mateu-Huertas E, Pantano L, Ferrer I, Guzmán M, Estivill X, Martí E.

PLoS Genet. 2012;8(2):e1002481. doi: 10.1371/journal.pgen.1002481. Epub 2012 Feb 23.

11.

Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.

Fiszer A, Ellison-Klimontowicz ME, Krzyzosiak WJ.

Acta Biochim Pol. 2016;63(4):759-764. Epub 2016 Oct 21.

12.

Identification of the porcine homologous of human disease causing trinucleotide repeat sequences.

Madsen LB, Thomsen B, Sølvsten CA, Bendixen C, Fredholm M, Jørgensen AL, Nielsen AL.

Neurogenetics. 2007 Aug;8(3):207-18. Epub 2007 May 22.

PMID:
17516099
13.

Autopsy-proven Huntington's disease with 29 trinucleotide repeats.

Kenney C, Powell S, Jankovic J.

Mov Disord. 2007 Jan;22(1):127-30.

PMID:
17115386
14.

A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, André VM, Cepeda C, Watson JB, Levine MS.

J Neurophysiol. 2012 Jan;107(2):677-91. doi: 10.1152/jn.00762.2011. Epub 2011 Nov 9.

15.

Faulty splicing and cytoskeleton abnormalities in Huntington's disease.

Fernández-Nogales M, Santos-Galindo M, Hernández IH, Cabrera JR, Lucas JJ.

Brain Pathol. 2016 Nov;26(6):772-778. doi: 10.1111/bpa.12430. Review. Erratum in: Brain Pathol. 2017 May;27(3):408.

PMID:
27529534
16.

CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Thion MS, Tézenas du Montcel S, Golmard JL, Vacher S, Barjhoux L, Sornin V, Cazeneuve C, Bièche I, Sinilnikova O, Stoppa-Lyonnet D, Durr A, Humbert S.

Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.

17.

MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice.

Tomé S, Manley K, Simard JP, Clark GW, Slean MM, Swami M, Shelbourne PF, Tillier ER, Monckton DG, Messer A, Pearson CE.

PLoS Genet. 2013;9(2):e1003280. doi: 10.1371/journal.pgen.1003280. Epub 2013 Feb 28.

19.

Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels.

Shin A, Shin B, Shin JW, Kim KH, Atwal RS, Hope JM, Gillis T, Leszyk JD, Shaffer SA, Lee R, Kwak S, MacDonald ME, Gusella JF, Seong IS, Lee JM.

Hum Mol Genet. 2017 Apr 1;26(7):1258-1267. doi: 10.1093/hmg/ddx033.

20.

Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).

Khan E, Tawani A, Mishra SK, Verma AK, Upadhyay A, Kumar M, Sandhir R, Mishra A, Kumar A.

ACS Chem Biol. 2018 Jan 19;13(1):180-188. doi: 10.1021/acschembio.7b00699. Epub 2017 Dec 18.

PMID:
29172480

Supplemental Content

Support Center